{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T09:14:29Z","timestamp":1760346869272,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s13730-020-00452-2","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T20:41:30Z","timestamp":1580244090000},"page":"189-194","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01"],"prefix":"10.1007","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5941-5679","authenticated-orcid":false,"given":"Arata","family":"Hibi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuto","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Hata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihisa","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,28]]},"reference":[{"key":"452_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01506","author":"G Genovese","year":"2019","unstructured":"Genovese G, Di Zenzo G, Cozzani E, Berti E, Cugno M, Marzano AV. New insights into the pathogenesis of bullous pemphigoid: 2019 update. Front Immunol. 2019. https:\/\/doi.org\/10.3389\/fimmu.2019.01506.","journal-title":"Front Immunol"},{"key":"452_CR2","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","volume":"136","author":"K Izumi","year":"2016","unstructured":"Izumi K, Nishie W, Mai Y, Wada M, Natsuga K, Ujiie H, et al. Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid. J Investig Dermatol. 2016;136:2201\u201310.","journal-title":"J Investig Dermatol"},{"key":"452_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/jamadermatol.2017.5465","volume":"154","author":"K Nakama","year":"2018","unstructured":"Nakama K, Koga H, Ishii N, Ohata C, Hashimoto T, Nakama T. Clinical and immunological profiles of 14 patients with bullous pemphigoid without IgG autoantibodies to the BP180 NC16A domain. JAMA Dermatol. 2018;154:347\u201350.","journal-title":"JAMA Dermatol"},{"key":"452_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01752","author":"Y Liu","year":"2017","unstructured":"Liu Y, Li L, Xia Y. BP180 is critical in the autoimmunity of bullous pemphigoid. Front Immunol. 2017. https:\/\/doi.org\/10.3389\/fimmu.2017.01752.","journal-title":"Front Immunol"},{"key":"452_CR5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.47102\/annals-acadmedsg.V44N4p119","volume":"44","author":"SC Cai","year":"2015","unstructured":"Cai SC, Lim YL, Li W, Allen JC, Chua SH, Tan SH, et al. Anti-BP180 NC16A IgG titres as an indicator of disease activity and outcome in asian patients with bullous pemphigoid. Ann Acad Med Singapore. 2015;44:119\u201326.","journal-title":"Ann Acad Med Singapore"},{"key":"452_CR6","first-page":"72","volume":"99","author":"K Kridin","year":"2019","unstructured":"Kridin K, Shihade W, Bergman R. Mortality in patients with bullous pemphigoid: a retrospective cohort study, systematic review and meta-analysis. Acta Derm Venereol. 2019;99:72\u20137.","journal-title":"Acta Derm Venereol"},{"key":"452_CR7","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/jdv.12366","volume":"28","author":"PG Stavropoulos","year":"2014","unstructured":"Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol. 2014;28:1133\u201340.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"452_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1592\/phco.27.8.1163","volume":"27","author":"AK Langley","year":"2007","unstructured":"Langley AK, Suffoletta TJ, Jennings HR. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy. 2007;27:1163\u201380.","journal-title":"Pharmacotherapy"},{"key":"452_CR9","doi-asserted-by":"publisher","first-page":"840","DOI":"10.4239\/wjd.v6.i6.840","volume":"6","author":"Y Nakamura","year":"2015","unstructured":"Nakamura Y, Hasegawa H, Tsuji M, Udaka Y, Mihara M, Shimizu T, et al. Diabetes therapies in hemodialysis patients: dipeptidase-4 inhibitors. World J Diabetes. 2015;6:840\u20139.","journal-title":"World J Diabetes"},{"key":"452_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s41100-018-0183-6","author":"I Masakane","year":"2018","unstructured":"Masakane I, Taniguchi M, Nakai S, Tsuchida K, Wada A, Ogata S, et al. Annual dialysis data report 2016, JSDT Renal Data Registry. Ren Replace Ther. 2018. https:\/\/doi.org\/10.1186\/s41100-018-0183-6.","journal-title":"Ren Replace Ther"},{"key":"452_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.12781","volume":"185","author":"C Klemann","year":"2016","unstructured":"Klemann C, Wagner L, Stephan M, von H\u00f6rsten S. Cut to the chase: a review of CD26\/dipeptidyl peptidase-4\u2019s (DPP4) entanglement in the immune system. Clin Exp Immunol. 2016;185:1\u201321.","journal-title":"Clin Exp Immunol"},{"key":"452_CR12","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.jid.2017.11.023","volume":"138","author":"H Ujiie","year":"2018","unstructured":"Ujiie H, Muramatsu K, Mushiroda T, Ozeki T, Miyoshi H, Iwata H, et al. HLA-DQB1*03:01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP-4 inhibitors. J Investig Dermatol. 2018;138:1201\u20134.","journal-title":"J Investig Dermatol"},{"key":"452_CR13","doi-asserted-by":"publisher","first-page":"689","DOI":"10.4269\/ajtmh.16-0273","volume":"95","author":"DQ Luo","year":"2016","unstructured":"Luo DQ, Huang MX, Liu JH, Tang W, Zhao YK, Sarkar R. Bullous scabies. Am J Trop Med Hyg. 2016;95:689\u201393.","journal-title":"Am J Trop Med Hyg"},{"key":"452_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2215\/CJN.05900513","volume":"9","author":"TA Galperin","year":"2014","unstructured":"Galperin TA, Cronin AJ, Leslie KS. Cutaneous manifestations of ESRD. Clin J Am Soc Nephrol. 2014;9:201\u201318.","journal-title":"Clin J Am Soc Nephrol"},{"key":"452_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0272-6386(85)80006-8","volume":"5","author":"KD Lempert","year":"1985","unstructured":"Lempert KD, Baltz PS, Welton WA, Whittier FC. Pseudouremic pruritus: a scabies epidemic in a dialysis unit. Am J Kidney Dis. 1985;5:117\u20139.","journal-title":"Am J Kidney Dis"},{"key":"452_CR16","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/jdv.12132","volume":"28","author":"SD Chung","year":"2014","unstructured":"Chung SD, Lin HC, Wang KH. Increased risk of pemphigoid following scabies: a population-based matched-cohort study. J Eur Acad Dermatol Venereol. 2014;28:558\u201364.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"452_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1468-3083.2011.04062.x","volume":"26","author":"K Skandalis","year":"2012","unstructured":"Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol. 2012;26:249\u201353.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"452_CR18","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamadermatol.2015.2939","volume":"152","author":"R Haber","year":"2016","unstructured":"Haber R, Fayad AM, Stephan F, Obeid G, Tomb R. Bullous pemphigoid associated with linagliptin treatment. JAMA Dermatol. 2016;152:224\u20136.","journal-title":"JAMA Dermatol"},{"key":"452_CR19","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14601","volume":"175","author":"J B\u00e9n\u00e9","year":"2016","unstructured":"B\u00e9n\u00e9 J, Moulis G, Bennani I, Auffret M, Coupe P, Babai S, et al. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case\u2013noncase study in the French Pharmacovigilance Database. Br J Dermatol. 2016;175:296\u2013301.","journal-title":"Br J Dermatol"},{"key":"452_CR20","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/jdi.12877","volume":"10","author":"Y Kawaguchi","year":"2019","unstructured":"Kawaguchi Y, Shimauchi R, Nishibori N, Kawashima K, Oshitani S, Fujiya A, et al. Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: a retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients. J Diabetes Investig. 2019;10:392\u20138.","journal-title":"J Diabetes Investig"},{"key":"452_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13100","author":"K Phan","year":"2019","unstructured":"Phan K, Charlton O, Smith SD. Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: a systematic review and adjusted meta-analysis. Australas J Dermatol. 2019. https:\/\/doi.org\/10.1111\/ajd.13100.","journal-title":"Australas J Dermatol"},{"key":"452_CR22","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.2337\/dc18-0210","volume":"41","author":"M Arai","year":"2018","unstructured":"Arai M, Shirakawa J, Konishi H, Sagawa N, Terauchi Y. Bullous pemphigoid and dipeptidyl peptidase 4 inhibitors: a disproportionality analysis based on the Japanese Adverse Drug Event Report Database. Diabetes Care. 2018;41:e130\u2013e132132.","journal-title":"Diabetes Care"},{"key":"452_CR23","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/1346-8138.14741","volume":"46","author":"H Tanaka","year":"2019","unstructured":"Tanaka H, Ishii T. Analysis of patients with drug-induced pemphigoid using the Japanese Adverse Drug Event Report database. J Dermatol. 2019;46:240\u20134.","journal-title":"J Dermatol"},{"key":"452_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13060","author":"T Murakami","year":"2019","unstructured":"Murakami T, Yabe D, Inagaki N. Bullous pemphigoid with dipeptidyl peptidase-4 inhibitors: clinical features and pathophysiology. J Diabetes Investig. 2019. https:\/\/doi.org\/10.1111\/jdi.13060.","journal-title":"J Diabetes Investig"},{"key":"452_CR25","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2337\/dc19-0409","volume":"42","author":"A Douros","year":"2019","unstructured":"Douros A, Rouette J, Yin H, Yu OHY, Filion KB, Azoulay L. Dipeptidyl peptidase 4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes. Diabetes Care. 2019;42:1496\u2013503.","journal-title":"Diabetes Care"},{"key":"452_CR26","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","volume":"78","author":"M Benzaquen","year":"2018","unstructured":"Benzaquen M, Borradori L, Berbis P, Cazzaniga S, Valero R, Richard MA, et al. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland. J Am Acad Dermatol. 2018;78:1090\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"452_CR27","doi-asserted-by":"publisher","first-page":"647","DOI":"10.4009\/jsdt.50.647","volume":"50","author":"GR Shrestha","year":"2017","unstructured":"Shrestha GR, Matsumoto A, Tarutani M. Bullous pemphigoid induced by vildagliptin: a case involving a maintenance hemodialysis patient. J Jpn Soc Dial Ther. 2017;50:647\u201352 (in Japanese).","journal-title":"J Jpn Soc Dial Ther"},{"key":"452_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01439","author":"K Izumi","year":"2019","unstructured":"Izumi K, Nishie W, Beniko M, Shimizu H. A cross-sectional study comparing the prevalence of bullous pemphigoid autoantibodies in 275 cases of type II diabetes mellitus treated with or without dipeptidyl peptidase-IV inhibitors. Front Immunol. 2019. https:\/\/doi.org\/10.3389\/fimmu.2019.01439.","journal-title":"Front Immunol"},{"key":"452_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01224","author":"Y Mai","year":"2019","unstructured":"Mai Y, Nishie W, Izumi K, Shimizu H. Preferential reactivity of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid autoantibodies to the processed extracellular domains of BP180. Front Immunol. 2019. https:\/\/doi.org\/10.3389\/fimmu.2019.01224.","journal-title":"Front Immunol"},{"key":"452_CR30","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S0190-9622(84)70266-0","volume":"11","author":"TY Chuang","year":"1984","unstructured":"Chuang TY, Korkij W, Soltani K, Clayman J, Cook J. Increased frequency of diabetes mellitus in patients with bullous pemphigoid: a case\u2013control study. J Am Acad Dermatol. 1984;11:1099\u2013102.","journal-title":"J Am Acad Dermatol"},{"key":"452_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000058395","volume":"91","author":"K Nakao","year":"2002","unstructured":"Nakao K, Nagake Y, Okamoto A, Ichikawa H, Yamamura M, Makino H. Serum levels of soluble CD26 and CD30 in patients on hemodialysis. Nephron. 2002;91:215\u201321.","journal-title":"Nephron"},{"key":"452_CR32","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/ki.1993.123","volume":"43","author":"B Descamps-Latscha","year":"1993","unstructured":"Descamps-Latscha B, Herbelin A, Nguyen AT, de Groote D, Chauveau P, Verger C, et al. Soluble CD23 as an effector of immune dysregulation in chronic uremia and dialysis. Kidney Int. 1993;43:878\u201384.","journal-title":"Kidney Int"},{"key":"452_CR33","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.1346-8138.1995.tb03394.x","volume":"22","author":"N Maekawa","year":"1995","unstructured":"Maekawa N, Hosokawa H, Soh H, Kasahara M, Izumi H, Yodoi J, et al. Serum levels of soluble CD23 in patients with bullous pemphigoid. J Dermatol. 1995;22:310\u20135.","journal-title":"J Dermatol"},{"key":"452_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jdermsci.2004.03.009","volume":"35","author":"M Inaoki","year":"2004","unstructured":"Inaoki M, Sato S, Takehara K. Elevated expression of CD23 on peripheral blood B lymphocytes from patients with bullous pemphigoid: correlation with increased serum IgE. J Dermatol Sci. 2004;35:53\u20139.","journal-title":"J Dermatol Sci"},{"key":"452_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/bjd.15114","volume":"177","author":"T Hashimoto","year":"2017","unstructured":"Hashimoto T, Ohzono A, Teye K, Numata S, Hiroyasu S, Tsuruta D, et al. Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid. Br J Dermatol. 2017;177:141\u201351.","journal-title":"Br J Dermatol"},{"key":"452_CR36","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.jid.2018.02.021","volume":"138","author":"Y Sun","year":"2018","unstructured":"Sun Y, Liu H, Wang Z, Fu X, Wang C, Mi Z, et al. The HLA-DQB1*03:01 is associated with bullous pemphigoid in the Han Chinese population. J Investig Dermatol. 2018;138:1874\u20137.","journal-title":"J Investig Dermatol"},{"key":"452_CR37","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/1346-8138.13031","volume":"43","author":"S D\u0103nescu","year":"2016","unstructured":"D\u0103nescu S, Chiorean R, Macovei V, Sitaru C, Baican A. Role of physical factors in the pathogenesis of bullous pemphigoid: case report series and a comprehensive review of the published work. J Dermatol. 2016;43:134\u201340.","journal-title":"J Dermatol"},{"key":"452_CR38","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/iwj.12670","volume":"14","author":"K Osipowicz","year":"2017","unstructured":"Osipowicz K, Kalinska-Bienias A, Kowalewski C, Wozniak K. Development of bullous pemphigoid during the haemodialysis of a young man: case report and literature survey. Int Wound J. 2017;14:288\u201392.","journal-title":"Int Wound J"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-020-00452-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13730-020-00452-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-020-00452-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T05:37:39Z","timestamp":1665639459000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13730-020-00452-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,28]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["452"],"URL":"https:\/\/doi.org\/10.1007\/s13730-020-00452-2","relation":{},"ISSN":["2192-4449"],"issn-type":[{"type":"electronic","value":"2192-4449"}],"subject":[],"published":{"date-parts":[[2020,1,28]]},"assertion":[{"value":"6 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interests associated with this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The article does not contain involving human or animal participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consent was obtained from the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}